Open access
Sep 2026
16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy
ABBV-CLS-484 is tolerable, with preliminary evidence of clinical activity in dose escalation, and additional strategies that combine ABBV-CLS-484 with VEGF TKIs, CAR-T therapy, and T cell engagers are being tested in preclinical models.
H. Hammers, E. Calvo, B. Carneiro et al.
· The Oncologist · 0 citations